PharmaCorp Files Q3 2024 Financial Statements and MD&A
26 Noviembre 2024 - 8:30PM
PHARMACORP RX INC. (“
PharmaCorp”
or the “
Corporation”) (TSXV: PCRX) is pleased to
announce the filing on SEDAR+ of its unaudited financial statements
together with associated MD&A for the three and nine months
ended September 30, 2024. To review the Corporation’s Q3 2024
unaudited financial statements and associated MD&A please visit
SEDAR+ at www.sedarplus.ca.
About PharmaCorp Rx Inc.
PharmaCorp currently operates three PharmaChoice
bannered pharmacies in Canada and will continue to acquire
PharmaChoice Canada branded pharmacies as they come to market in
conjunction with its strategic alliance agreement with PharmaChoice
Canada. The Corporation will also acquire independently owned
non-PharmaChoice Canada bannered pharmacies in Canada, and
thereafter, continue to operate such acquired pharmacies under a
PharmaChoice Canada banner. PharmaCorp shares trade on the TSX
Venture Exchange under the symbol: PCRX.
For further information,
contact:
Mr. Alan SimpsonSuite #203, 303 Wellman Lane,
Saskatoon, SK S7T 0J1 Tel: (306) 536-3771
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
PharmaCorp RX (TSXV:PCRX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
PharmaCorp RX (TSXV:PCRX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024